piramil 5 mg 5 mg tabletki
medezin sp. z o.o. - ramiprilum - tabletki - 5 mg
piramil 10 mg 10 mg tabletki
medezin sp. z o.o. - ramiprilum - tabletki - 10 mg
piramil 5 mg tabletki
delfarma sp. z o.o. - ramiprilum - tabletki - 5 mg
piramil 10 mg 10 mg tabletki
inpharm sp. z o.o. - ramiprilum - tabletki - 10 mg
piramil 5 mg 5 mg tabletki
inpharm sp. z o.o. - ramiprilum - tabletki - 5 mg
vyvgart
argenx - efgartigimod alfa - myasthenia gravis - leki immunosupresyjne - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroksysmal - selektywne leki immunosupresyjne - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
dolokadin 750 mg tabletki
dr. kade pharmazeutische fabrik gmbh - methocarbamolum - tabletki - 750 mg
soliris
alexion europe sas - Экулизумаб - hemoglobinuria, paroksysmal - leki immunosupresyjne - Солирис wskazany dla dorosłych i dzieci w leczeniu:napadowa nocna hemoglobinuria (pnh). dowodów na efekt kliniczny objawia się u pacjentów z hemolizy z kliniczny objaw(y), świadczy o dużej aktywności choroby, niezależnie od historii transfuzji (patrz rozdział 5. nietypowy zespół hemolityczno-mocznicowy (Агус). Солирис jest wskazany u dorosłych w leczeniu:ogniotrwałe uogólnione z miastenią (ГГМ) u pacjentów z anty-ацетилхолиновому receptora (АЧР) przeciwciała (patrz rozdział 5. zaburzenia neuromyelitis nerwu widma (nmosd) u pacjentów, którzy są anty-akwaporyna-4 (aqp4) przeciwciała z nawracającymi upływem choroby.
tonicard 150 mg tabletki powlekane
accord healthcare polska sp. z o.o. - propafenoni hydrochloridum - tabletki powlekane - 150 mg